Trovagene to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference

SAN DIEGO, July 5, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today announced that its Chief Executive Officer, Bill Welch, will present a corporate overview at the 2nd Annual Cantor Fitzgerald Healthcare Conference taking place July 12-13, 2016 at Le Parker Meridian Hotel, NY.

Trovagene is scheduled to present on Wednesday, July 13, 2016 at 3:30 pm EDT. The Company's Chief Executive Officer, Bill Welch, and Chief Scientific Officer, Mark Erlander, Ph.D., will be available for one-on-one meetings during the conference. The presentation will be webcast live at http://wsw.com/webcast/cantor4/trov and can also be accessed through the investor relations web page at www.trovagene.com. A replay of the presentation will be available at www.trovagene.com and will be archived for 90 days. 

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary Precision Cancer Monitoring® (PCM) technology for the detection and monitoring of circulating tumor DNA (ctDNA) in urine. The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's PCM technology is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend," or other similar terms or expressions that concern Trovagene's expectations, strategy, plans or intentions. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that our Precision Cancer Monitoring® platform will be utilized by oncologists or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2015 and its other periodic reports filed with the Securities and Exchange Commission.

Trovagene Contacts

Logo - http://photos.prnewswire.com/prnh/20160520/370471LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trovagene-to-present-at-the-2nd-annual-cantor-fitzgerald-healthcare-conference-300294346.html

SOURCE Trovagene, Inc.